Early Positive Signs in CAR T-Cell Therapy Trial |
Chimeric Therapeutics is reporting early signs of efficacy in the world’s first clinical trial of CAR T-cell therapy for neuroendocrine cancer. The first NET patient to receive the treatment had stable disease after 60 days and was feeling well. The clinical trial has also been expanded to a fourth site. Read more about this historic trial and NETRF’s role in making it possible.
|
|
|
A New Treatment Option for NET Patients |
The U.S. Food and Drug Administration (FDA) has recently approved cabozantinib for adults and children over 12 with previously treated, unresectable, advanced pancreatic (pNET) and extra-pancreatic (epNET) tumors. Cabozantinib is marketed as CABOMETYX by Exelixis.
The FDA approval follows the results from the pivotal CABINET trial, where cabozantinib extended progression-free survival in participants epNETs to 8.4 months compared to 3.9 months in those receiving a placebo. Progression-free survival was extended to 13.8 months in participants with pNETs who received cabozantinib compared with 4.4 months in those who received a placebo. Read more.
|
| COMPETE Trial of Radiopharmaceutical ITM-11 Shows Efficacy in GEP-NETs |
Promising results of the Phase 3 COMPETE trial for patients with inoperable, progressive Grade 1 and Grade 2 gastroenteropancreatic neuroendocrine tumors (GEP-NETs) were announced at the ENETS conference in Krakow. ITM-11, a targeted radiopharmaceutical therapy, significantly extended progression-free survival compared to everolimus, a current standard of care.
Read more about the COMPETE trial.
|
|
|
Breakthroughs Can’t Wait — Neuroendocrine Cancer Research Is at a Critical Crossroads |
Neuroendocrine cancer research stands at a tipping point. For too long, it has been drastically underfunded — and now, as other funding declines, the pressure on private support is greater than ever. Yet, at the very moment when resources are shrinking, momentum is building. Researchers are poised for transformative breakthroughs that could redefine how we detect, treat, and ultimately cure this disease.
NETRF has seen a 70% surge in requests for our funding since 2023— a powerful sign that innovation in the field is accelerating. Scientists are ready. The ideas are there. But without urgent funding, this progress could come to a standstill.
NETRF is the global leader — and often the only source — of funding for neuroendocrine cancer researchers. Without us, this vital work simply won’t happen.
If we don’t fund it, no one else will. And we risk delaying cures for years — even decades.
This is our moment to act. Your gift fuels breakthroughs today and makes cures possible tomorrow.
Please donate now to ensure that the most promising research continues to move forward — research that brings hope to patients and families everywhere.
|
|
|
NETRF Grantees Recognized for their Expertise at ENETS |
|
|
|
NETRF grantees made a strong showing at the 2022 ENETS (European Neuroendocrine Tumor Society) conference in Krakow, Poland, where more than 1000 participants gathered to discuss the latest basic and clinical research. Twenty NETRF grantees presented their work or moderated sessions.
Read more about those who won awards.
|
|
|
Cell Models Consortium Update |
|
|
Cell models are essential for understanding neuroendocrine cancer biology and testing new therapies. Modeling neuroendocrine tumors (NETs) in the laboratory has historically been challenging because NETs are often slow-growing and genetically diverse. The lack of effective models has hindered drug development and limited our ability to tailor treatments to individual patients. Now a group of NET experts has formed the NET Models Consortium to pool expertise in assessing available models, their limitations, and how to develop new, effective models. Read more.
|
| |
|
When it comes to peptide receptor radionuclide therapy (PRRT), patients may have questions and concerns. In this episode, we dive into the most common questions surrounding PRRT and the broader field of radiopharmaceutical treatments for neuroendocrine cancer. This is an exciting field where much research is being done to advance these treatments. In this NETWise episode, we feature key insights from doctors and researchers to help you better understand this important treatment option. Listen now.
Did you know that you can sign up to have NETRF notify you of the next NETWise podcast. Or you can find and subscribe to NETWise on your favorite podcast service.
|
Preparing for Your Specialist Visit |
Navigating a specialist visit can feel overwhelming, but being prepared can make all the difference. In this episode of the NETRF Thrivership Series, we explore practical strategies to help you make the most of your appointment. You'll learn a simple, easy-to-remember acronym to guide your preparation and ensure you leave with the information you need.
Plus, hear firsthand from Burt, Kelly, and Shane as they share their own tips and experiences on what works best for them. Whether you're newly diagnosed or managing ongoing care, these insights can help you approach your next visit with confidence.
|
|
|
|
NETRF’s Voice on the NETPact Committee |
Congratulations to our Director of Patient Education, Jessica Thomas, LCSW, for being selected to serve on the NANETS NETPact Committee. This committee is focused on advocating for patient access to care and reimbursement.
|
|
|
Making Strides for Neuroendocrine Cancer Research: Support Bennett Raphel in the Boston Marathon! |
On April 21, Bennett Raphel of Andover, MA, will lace up for the 129th Boston Marathon in honor of his aunt, who lived with neuroendocrine cancer for eight years before passing away last year. Running with a bib from his employer, Point32Health, Bennett is dedicating his 26.2-mile journey to raising funds for neuroendocrine cancer research—pushing forward in the race for better treatments and cures.
This will be Bennett’s second marathon, having also completed the NYC Marathon last year. Join him in making strides toward progress by donating today.
|
| Mark your calendars to support NETRF in 2025! |
|
|
Raising Funds, Raising Hope: Community Event Champions Connect |
|
|
|
On Tuesday, March 18, NETRF hosted a Community Fundraising Webinar, bringing together passionate fundraisers from coast to coast to share ideas, inspiration, and support for their events. From runs and golf tournaments to creative community fundraisers, participants connected to strengthen efforts to raise awareness and funds for neuroendocrine cancer research.
Missed the webinar?
Check out the presentation here.
|
|
|
Interested in hosting an event?
Reach out to Steve Perna at steve.perna@netrf.org to learn how you can get involved!
|
|
|
NETRF is looking for a creative, collaborative, mission-driven Director of Digital Communications! We have a respected brand, a 20-year history of success and an exciting future. Check out the job description to learn more.
|
| As of March 28, NETRF is moving our office. Our new home is:
100 Hancock Street, Third Floor
Quincy, Massachusetts 02171
Please make a note of our new address!
|
|
|
|
NET Research Foundation
100 Hancock Street,
Third floor
Quincy, MA 02171
(617) 946-1780 info@netrf.org
|
|
The mission of the Neuroendocrine Tumor Research Foundation is to fund research to discover cures and more effective treatments for neuroendocrine cancer. NETRF is the largest global funder of neuroendocrine research and a preeminent resource for expert patient education and support.
NETRF is a 501(c)(3) organization. All donations are tax-deductible to the extent allowed by law.
|
|
|
Manage your preferences | Opt Out using TrueRemove™
Got this as a forward? Sign up to receive our future emails.
View this email online.
|
100 Hancock Street Third Floor | Quincy, MA 02171 US
|
|
|
This email was sent to .
To continue receiving our emails, add us to your address book.
|
| |
|
|
